Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03942653 · ClinicalTrials.gov registry record · Phase 2
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
A Phase 2 study of Salivary Gland Carcinoma, sponsored by Manish Patel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT03942653: Recruiting Phase 2 study of Salivary Gland Carcinoma, sponsored by Manish Patel.
NCT03942653 is a Phase 2 study of Salivary Gland Carcinoma that is actively recruiting participants, run by Manish Patel. The registered enrollment target is 20 participants. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03942653, a Phase 2 study of Salivary Gland Carcinoma, is actively recruiting participants, sponsored by Manish Patel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Goserelin Acetate
Study Locations (7)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- University of Illinois Cancer Center - Chicago
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Maryland
- Univeristy of Maryland - Baltimore
Michigan
- University of Michigan Health System - Ann Arbor
Minnesota
- University of Minnesota: Masonic Cancer Center - Minneapolis
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03942653
The ClinicalTrials.gov registry entry for NCT03942653 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manish Patel, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Salivary Gland Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03942653 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Iowa, Maryland.
Frequently Asked Questions
What is clinical trial NCT03942653 about?
NCT03942653 is a clinical study titled "Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma". A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
What is the current status of trial NCT03942653?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-05-30. Estimated completion is 2026-08.
What conditions does trial NCT03942653 study?
This clinical trial studies the following conditions: Salivary Gland Carcinoma.
What interventions are being tested in trial NCT03942653?
The interventions under investigation include: Pembrolizumab (DRUG), Goserelin Acetate (DRUG).
Who is sponsoring clinical trial NCT03942653?
This trial is sponsored by Manish Patel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03942653 being conducted?
This trial has 7 study locations across Illinois, Iowa, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.